CC-671
(CC671;4-(4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide;CS-2792;CC-671;Inhibitor,inhibit,Cyclin dependent kinase,CC671,CC-671,CC 671,CDK;Benzamide, 4-[[4-(cyclopentyloxy)-5-(2-methyl-6-benzoxazolyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxy-N-methyl-;CC-671, 10 mM in DMSO
CC-671, is a novel dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) inhibitor for the treatment of triple negative breast cancer initiated from a phenotypic screen.
